2023-12-20 18:35:00来源：2024年美国临床肿瘤学会泌尿男生殖系肿瘤分会（ASCO-GU）年会 医脉通编译阅读：66次
2024年美国临床肿瘤学会泌尿男生殖系肿瘤分会（ASCO-GU）年会将于当地时间2024年1月25日至27日在旧金山盛大召开。ASCO GU是泌尿男生殖系肿瘤领域的学术盛会，会议将展示该领域最具创新性的科学进展，并探讨泌尿男生殖系肿瘤未来的治疗方向。多项国外泌尿男生殖系肿瘤重磅研究即将公布，医脉通精选整理如下，邀您一览！
General Session
全体大会
摘要号：15
标题：Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
讲者：Neal D. Shore
时间：2024/1/25 GMT-8 14:30
摘要号：529
标题：Correlation of urinary comprehensive genomic profile with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605.
讲者：Marie-Pier St-Laurent
时间：2024/1/26 GMT-8 13:50
摘要号：528
标题：Estimating the impact of adjuvant treatment with nivolumab on long-term survivorship rates compared with surveillance: Analyses of disease-free survival (DFS) from the phase 3 CheckMate-274 trial.
讲者：Daniel M. Geynisman
时间：2024/1/26 GMT-8 15:20
Oral Abstract Session
口头报告专场
摘要号：19
标题：BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).
讲者：Maha H. A. Hussain
时间：2024/1/25 GMT-8 08:15
摘要号：18
标题：CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
讲者：Neeraj Agarwal
时间：2024/1/25 GMT-8 08:25
摘要号：260
标题：Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP).
讲者：Karen E. Hoffman
时间：2024/1/25 GMT-8 08:57
摘要号：LBA530
标题：Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.
讲者： Michiel Simon Van Der Heijden
时间：2024/1/26 GMT-8 16：15
摘要号：539
标题：Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab).
讲者：Rohit K. Jain
时间：2024/1/26 GMT-8 16：25
摘要号：LBA531
标题：AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.
讲者：Andrea B. Apolo
时间：2024/1/26 GMT-8 16:47
摘要号：LBA358
标题：Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.
讲者：Robert J. Motzer
时间：2024/1/27 GMT-8 08:15
摘要号：LBA359
标题：Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).
讲者：Toni K. Choueiri
时间：2024/1/27 GMT-8 08:25
摘要号：LBA360
标题：Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.
讲者：Saby George
时间：2024/1/27 GMT-8 08:47
摘要号：LBA361
标题：Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.
讲者：Thomas Powles
时间：2024/1/27 GMT-8 08:57
Rapid Oral Abstract Session
快速口头报告专场
摘要号：20
标题：Multi-centre prospective evaluation of cognitive function in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) or enzalutamide (ENZ): The ACE study.
讲者：Amit Bahl
时间：2024/1/25 GMT-8 16:15
摘要号：121
标题：Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).
讲者：Himisha Beltran
时间：2024/1/25 GMT-8 16:25
摘要号：537
标题：Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study
讲者：Amanda Nizam
时间：2024/1/26 GMT-8 07:50
摘要号：534
标题：Predictive value of dynamic changes in ctDNA and baseline biomarkers with neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
讲者：Matthew Nicholas Young
时间：2024/1/26 GMT-8 08:05
摘要号：632
标题：Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC): Interim analysis of ANTICIPATE phase II trial.
讲者：Matt D. Galsky
时间：2024/1/26 GMT-8 08：15
摘要号：362
标题：Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.
讲者：Maria Teresa Bourlon
时间：2024/1/27 GMT-8 13:00
摘要号：363
标题：Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.
讲者：Nizar M. Tannir
时间：2024/1/27 GMT-8 13:05
摘要号：364
标题：Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial.
讲者：Viktor Grünwald
时间：2024/1/27 GMT-8 13:10
摘要号：1
标题：Cabozantinib plus atezolizumab in locally advanced/metastatic adrenocortical carcinoma: Results from a multi-cohort basket phase II trial, CABATEN/GETNE-T1914.
讲者： Enrique Grande
时间：2024/1/27 GMT-8 13:20
备注：排名不分先后，按照汇报时间进行排序
若您有感兴趣的研究，请留言告知我们，待会议摘要内容公布，我们将对其进行详细解读~